Verve Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Verve Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
Verve Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 27.8 %, a 14.9% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	27.8	+3.6	+14.9%	Jun 30, 2024
Q1 2024	27.4	+6.09	+28.5%	Mar 31, 2024
Q4 2023	27.2	+9.89	+57%	Dec 31, 2023
Q3 2023	26.6	+13.7	+106%	Sep 30, 2023
Q2 2023	24.2	+17	+237%	Jun 30, 2023
Q1 2023	21.3	+15.2	+244%	Mar 31, 2023
Q4 2022	17.4			Dec 31, 2022
Q3 2022	12.9			Sep 30, 2022
Q2 2022	7.19			Jun 30, 2022
Q1 2022	6.2			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.